{"transactions":[{"id":934504,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-21T21:47:42.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement."}],"balance_after":100000,"derivative":{"underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001133416-26-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000030/form4.xml","form_type":"4"}},{"id":934503,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-21T21:47:42.000Z","date":"2026-01-16","kind":"grant","planned":true,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027."}],"balance_after":65000,"derivative":{"exercise_price":3.04,"expiration_date":"2036-01-16","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-26-000030","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000030/form4.xml","form_type":"4"}},{"id":947582,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-01","kind":"exercise","planned":true,"acquired":false,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."},{"field":"shares","element":"transactionShares","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on January 2, 2026."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2026-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947581,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-06","kind":"sale","planned":true,"acquired":false,"shares":20354,"price":3.6698,"value":74695.1092,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $3.47 to $3.81. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947580,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-05","kind":"sale","planned":true,"acquired":false,"shares":25732,"price":3.8978,"value":100298.1896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $3.81 to $4.06. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":27968,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947579,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-02","kind":"sale","planned":true,"acquired":false,"shares":13914,"price":4.1968,"value":58394.2752,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $4.00 to $4.34. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":53700,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":947578,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-06T21:54:05.000Z","date":"2026-01-02","kind":"exercise","planned":true,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock Units."}],"balance_after":67614,"source":{"system":"sec-edgar","filing":"0001133416-26-000006","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341626000006/form4.xml","form_type":"4"}},{"id":994308,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock (right to buy)","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":false,"shares":18190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2034-01-26","underlying":"Common stock","underlying_shares":18190},"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994307,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":false,"shares":28120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":0,"derivative":{"exercise_price":1.98,"exercise_date":"2022-06-30","expiration_date":"2032-12-04","underlying":"Common stock","underlying_shares":28120},"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994306,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":2323,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026."}],"balance_after":48750,"derivative":{"exercise_price":1.23,"exercise_date":"2025-06-30","expiration_date":"2035-01-22","underlying":"Common stock","underlying_shares":2323},"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994305,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":19701,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":18190,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2034-01-26","underlying":"Common stock","underlying_shares":19701},"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994304,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":9586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":28120,"derivative":{"exercise_price":1.98,"exercise_date":"2022-06-30","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":9586},"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994303,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":18210,"price":6.223,"value":113320.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994302,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":true,"shares":18210,"price":1.11,"value":20213.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":25824,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994301,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"sale","planned":true,"acquired":false,"shares":28100,"price":6.223,"value":174866.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.30. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994300,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-18","kind":"exercise","planned":true,"acquired":true,"shares":28100,"price":1.98,"value":55638.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":35714,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994299,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":2323,"price":6.0317,"value":14011.6391,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994298,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":2323,"price":1.23,"value":2857.29,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":9937,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994297,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":19701,"price":6.0317,"value":118830.5217,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994296,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":19701,"price":1.11,"value":21868.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":27315,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994295,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":9586,"price":6.0317,"value":57819.8762,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.10. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":994294,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-19T21:01:12.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":9586,"price":1.98,"value":18980.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":17200,"source":{"system":"sec-edgar","filing":"0001133416-25-000057","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000057/form4.xml","form_type":"4"}},{"id":1002547,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":false,"shares":1736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vests as follows: 25% on June 30, 2025, with 25% scheduled to vest on each of December 31, 2025, June 30, 2026, on December 31, 2026."}],"balance_after":51073,"derivative":{"exercise_price":1.23,"exercise_date":"2025-06-30","expiration_date":"2035-01-22","underlying":"Common stock","underlying_shares":1736},"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002546,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":false,"shares":1675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":37891,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2034-01-26","underlying":"Common stock","underlying_shares":1675},"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002545,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":false,"shares":1880,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":37706,"derivative":{"exercise_price":1.98,"exercise_date":"0022-06-30","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":1880},"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002544,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":1736,"price":6.0298,"value":10467.7328,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002543,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":1736,"price":1.23,"value":2135.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":9350,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002542,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":1675,"price":6.0266,"value":10094.555,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002541,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":1675,"price":1.11,"value":1859.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":9289,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002540,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":1880,"price":6.022,"value":11321.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.14. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1002539,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-12T21:01:01.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":1880,"price":1.98,"value":3722.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":9694,"source":{"system":"sec-edgar","filing":"0001133416-25-000050","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000050/form4.xml","form_type":"4"}},{"id":1005089,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025."}],"balance_after":52809,"derivative":{"exercise_price":1.72,"exercise_date":"2024-06-30","expiration_date":"2034-01-22","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005088,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":39566,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2034-01-26","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005087,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":39586,"derivative":{"exercise_price":1.98,"exercise_date":"0022-06-30","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005086,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":200,"price":6,"value":1200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005085,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":1.72,"value":344.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7814,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005084,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":200,"price":6,"value":1200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005083,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":1.11,"value":222.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7814,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005082,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"sale","planned":true,"acquired":false,"shares":200,"price":6,"value":1200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1005081,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-07T21:07:39.000Z","date":"2025-11-05","kind":"exercise","planned":true,"acquired":true,"shares":200,"price":1.98,"value":396.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":7814,"source":{"system":"sec-edgar","filing":"0001133416-25-000047","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000047/form4.xml","form_type":"4"}},{"id":1007028,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":10741,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025."}],"balance_after":53009,"derivative":{"exercise_price":1.72,"exercise_date":"2024-06-30","expiration_date":"2034-01-22","underlying":"Common stock","underlying_shares":10741},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007027,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":8974,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":39766,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2034-01-26","underlying":"Common stock","underlying_shares":8974},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007026,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":false,"shares":8914,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":39786,"derivative":{"exercise_price":1.98,"exercise_date":"0022-06-30","expiration_date":"2032-01-24","underlying":"Common stock","underlying_shares":8914},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007025,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options vested as follows: 25% on each of June 30, 2024, December 31, 2024, and June 30, 2025, with 25% scheduled to vest on December 31, 2025."}],"balance_after":63750,"derivative":{"exercise_price":1.72,"exercise_date":"2024-06-30","expiration_date":"2034-01-22","underlying":"Comm stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007024,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":false,"shares":1260,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vested as follows: 25% on each of June 30, 2023, December 31, 2023, June 30, 2024, and December 31, 2024."}],"balance_after":48740,"derivative":{"exercise_price":1.11,"exercise_date":"2023-06-30","expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":1260},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007023,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":false,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on each of June 30, 2022, December 31, 2022, June 30, 2023, and December 31, 2023."}],"balance_after":48700,"derivative":{"exercise_price":1.98,"exercise_date":"2022-06-30","expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":1300},"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007022,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":10741,"price":6.07,"value":65197.87,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007021,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":10741,"price":1.72,"value":18474.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":18355,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007020,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":8974,"price":6.07,"value":54472.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007019,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":8974,"price":1.11,"value":9961.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":16588,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007018,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"sale","planned":true,"acquired":false,"shares":8914,"price":6.07,"value":54107.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.25. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007017,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-04","kind":"exercise","planned":true,"acquired":true,"shares":8914,"price":1.98,"value":17649.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":16528,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007016,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Commno stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":1250,"price":6.01,"value":7512.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007015,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":1.72,"value":2150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":8864,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007014,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":1260,"price":6.01,"value":7572.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007013,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":true,"shares":1260,"price":1.11,"value":1398.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":8874,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007012,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"sale","planned":true,"acquired":false,"shares":1300,"price":6.01,"value":7813.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1007011,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-11-05T21:06:19.000Z","date":"2025-11-03","kind":"exercise","planned":true,"acquired":true,"shares":1300,"price":1.98,"value":2574.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":8914,"source":{"system":"sec-edgar","filing":"0001133416-25-000043","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000043/form4.xml","form_type":"4"}},{"id":1040812,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-09-15T16:45:26.000Z","date":"2025-09-12","kind":"exercise","planned":true,"acquired":false,"shares":8706,"price":1.37,"value":11927.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":0,"derivative":{"exercise_price":1.37,"exercise_date":"2019-01-20","expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":8706},"source":{"system":"sec-edgar","filing":"0001133416-25-000039","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000039/form4.xml","form_type":"4"}},{"id":1040811,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-15T16:45:26.000Z","date":"2025-09-12","kind":"sale","planned":true,"acquired":false,"shares":8706,"price":6.4385,"value":56053.581,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares were sold in multiple transactions at prices ranging from $6.33 to $6.68. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-25-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000039/form4.xml","form_type":"4"}},{"id":1040810,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-09-15T16:45:26.000Z","date":"2025-09-12","kind":"exercise","planned":true,"acquired":true,"shares":8706,"price":1.37,"value":11927.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the SEC on August 14, 2025."}],"balance_after":16320,"source":{"system":"sec-edgar","filing":"0001133416-25-000039","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000039/form4.xml","form_type":"4"}},{"id":1294680,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2025-01-27T21:02:20.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% on the earlier of December 31, 2025 or signing of a partnership agreement."}],"balance_after":60000,"derivative":{"underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001133416-25-000004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000004/form4.xml","form_type":"4"}},{"id":1294679,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-01-27T21:02:20.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2025; December 31, 2025; June 30, 2026; and December 31, 2026."}],"balance_after":65000,"derivative":{"exercise_price":1.23,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-25-000004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341625000004/form4.xml","form_type":"4"}},{"id":1322066,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2024-12-26T13:18:04.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units disposed upon conversion into shares of common stock pursuant to vesting on December 20, 2024."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-24-000068","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000068/form4.xml","form_type":"4"}},{"id":1322065,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-26T13:18:04.000Z","date":"2024-12-23","kind":"sale","planned":true,"acquired":false,"shares":40000,"price":0.8873,"value":35492.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares of common stock sold pursuant to previously disclosed 10b5-1 plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Multiple transactions ranging from $0.92 t0 $0.85 with an average price of $0.8873."}],"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-24-000068","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000068/form4.xml","form_type":"4"}},{"id":1322064,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-12-26T13:18:04.000Z","date":"2024-12-23","kind":"exercise","planned":true,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of common stock acquired for no additional consideration resulting from vesting of Restricted Stock units."}],"balance_after":47614,"source":{"system":"sec-edgar","filing":"0001133416-24-000068","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000068/form4.xml","form_type":"4"}},{"id":1655580,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Unit","published_at":"2024-02-07T21:44:42.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Restricted Stock Units vest 100% upon public announcement of Interim Analysis data from NAVIGATE clinical trial if such announcement is made on or before December 31, 2024 or they will expire unvested."}],"balance_after":40000,"derivative":{"underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001133416-24-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000010/form4.xml","form_type":"4"}},{"id":1655579,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-07T21:44:42.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2024; December 31, 2024; June 30, 2025; and December 31, 2025."}],"balance_after":65000,"derivative":{"exercise_price":1.72,"expiration_date":"2034-01-24","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001133416-24-000010","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341624000010/form4.xml","form_type":"4"}},{"id":2042452,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-30T21:38:36.000Z","date":"2023-01-26","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2023; December 31, 2023; June 30, 2024; and December 31, 2024."}],"balance_after":50000,"derivative":{"exercise_price":1.11,"expiration_date":"2033-01-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-23-000016","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341623000016/form4.xml","form_type":"4"}},{"id":2112734,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-11-17T15:38:05.000Z","date":"2022-11-17","kind":"purchase","acquired":true,"shares":4000,"price":1.32,"value":5280.0,"ownership":{"direct":true},"balance_after":7614,"source":{"system":"sec-edgar","filing":"0001133416-22-000101","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000101/form4.xml","form_type":"4"}},{"id":2426929,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-25T21:19:32.000Z","date":"2022-01-24","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2022; December 31, 2022; June 30, 2023; and December 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":1.98,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001133416-22-000018","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000113341622000018/form4.xml","form_type":"4"}},{"id":2769587,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:17.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Such options vest when (i) the Company has received the interim results of its NAVIGATE clinical trial and (ii) makes a public announcement that it has received the interim results."}],"balance_after":100000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-21-013810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013810/doc4.xml","form_type":"4"}},{"id":2769586,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2021-03-29T20:35:17.000Z","date":"2021-03-25","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Such options vest as follows: 25% on each on September 30, 2021, March 31, 2022, September 30, 2022 and March 31, 2023."}],"balance_after":50000,"derivative":{"exercise_price":2.11,"expiration_date":"2031-03-25","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-21-013810","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924321013810/doc4.xml","form_type":"4"}},{"id":3312686,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2020-01-13T22:58:17.000Z","date":"2020-01-09","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The options were issued pursuant to the Galectin Therapeutics Inc. 2019 Omnibus Equity Incentive Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest as follows: 25% on each of June 30, 2020, December 31, 2020, June 30, 2021, and December 31, 2021."}],"balance_after":50000,"derivative":{"exercise_price":2.86,"expiration_date":"2030-01-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-20-001115","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000089924320001115/doc4.xml","form_type":"4"}},{"id":3505074,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock Purchase Warrant (right to buy)","published_at":"2019-06-03T21:45:02.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":7847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Each warrant is exerciseable for 0.075 shares of Common Stock of the Company."}],"balance_after":7847,"derivative":{"exercise_price":7,"exercise_date":"2019-11-30","expiration_date":"2026-05-31","underlying":"Common Stock","underlying_shares":585},"source":{"system":"sec-edgar","filing":"0001179022-19-000037","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000037/edgar.xml","form_type":"4"}},{"id":3505073,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-06-03T21:45:02.000Z","date":"2019-05-31","kind":"purchase","acquired":true,"shares":2354,"price":4.28,"value":10075.12,"ownership":{"direct":true},"balance_after":3614,"source":{"system":"sec-edgar","filing":"0001179022-19-000037","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000037/edgar.xml","form_type":"4"}},{"id":3692134,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-01-18T22:16:52.000Z","date":"2019-01-16","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on each of June 30, 2019, December 31, 2019, June 30, 2020, and December 31, 2020."}],"balance_after":50000,"derivative":{"exercise_price":4.72,"expiration_date":"2029-01-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001179022-19-000010","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902219000010/edgar.xml","form_type":"4"}},{"id":3886243,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-20","kind":"exercise","acquired":false,"shares":97267,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016."}],"balance_after":0,"derivative":{"exercise_price":4.41,"expiration_date":"2023-07-01","underlying":"Common Stock","underlying_shares":97267},"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886242,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-19","kind":"exercise","acquired":false,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on January 29, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":0,"derivative":{"exercise_price":3.45,"expiration_date":"2025-01-29","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886241,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-19","kind":"exercise","acquired":false,"shares":102733,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vested as follows: (i) 12.5% on December 31, 2013, (ii) 25% on December 31, 2014, (iii) 25% on December 31, 2015, and (iv) 50% on December 31, 2016."}],"balance_after":97267,"derivative":{"exercise_price":4.41,"expiration_date":"2023-07-01","underlying":"Common Stock","underlying_shares":102733},"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886240,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-20","kind":"sale","acquired":false,"shares":97267,"price":8.0812,"value":786034.0804,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $8.0054 to $8.2592. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886239,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-20","kind":"exercise","acquired":true,"shares":97267,"price":4.41,"value":428947.47,"ownership":{"direct":true},"balance_after":98527,"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886238,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-19","kind":"sale","acquired":false,"shares":128733,"price":9.0108,"value":1159987.3164,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The shares were sold in multiple transactions at prices ranging from $9.00 to $9.0266. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886237,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-19","kind":"exercise","acquired":true,"shares":26000,"price":3.45,"value":89700.0,"ownership":{"direct":true},"balance_after":129993,"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3886236,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-21T20:18:37.000Z","date":"2018-06-19","kind":"exercise","acquired":true,"shares":102733,"price":4.41,"value":453052.53,"ownership":{"direct":true},"balance_after":103993,"source":{"system":"sec-edgar","filing":"0001179022-18-000056","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000056/edgar.xml","form_type":"4"}},{"id":3894210,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-14T20:34:17.000Z","date":"2018-06-11","kind":"exercise","acquired":false,"shares":9294,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":8706,"derivative":{"exercise_price":1.37,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":9294},"source":{"system":"sec-edgar","filing":"0001179022-18-000052","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000052/edgar.xml","form_type":"4"}},{"id":3894209,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-14T20:34:17.000Z","date":"2018-06-12","kind":"sale","acquired":false,"shares":9294,"price":7.0117,"value":65166.7398,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000052/edgar.xml","form_type":"4"}},{"id":3894208,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-14T20:34:17.000Z","date":"2018-06-12","kind":"exercise","acquired":true,"shares":9294,"price":1.37,"value":12732.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":10554,"source":{"system":"sec-edgar","filing":"0001179022-18-000052","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000052/edgar.xml","form_type":"4"}},{"id":3897139,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-11","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vested as follows: 25% on January 20, 2016, the grant date, with the remainder vesting ratably on a monthly basis over a three year period."}],"balance_after":18000,"derivative":{"exercise_price":1.37,"expiration_date":"2026-01-20","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3897138,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-08","kind":"exercise","acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":0,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3897137,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-11","kind":"sale","acquired":false,"shares":20000,"price":6.375,"value":127500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The shares were sold in multiple transactions at prices ranging from $6.25 to $6.50. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3897136,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-11","kind":"exercise","acquired":true,"shares":20000,"price":1.37,"value":27400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":21260,"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3897135,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-08","kind":"sale","acquired":false,"shares":100000,"price":5.75,"value":575000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The shares were sold in multiple transactions at prices ranging from $5.50 to $6.00. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3897134,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-12T20:48:49.000Z","date":"2018-06-08","kind":"exercise","acquired":true,"shares":100000,"price":0.87,"value":87000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":101260,"source":{"system":"sec-edgar","filing":"0001179022-18-000048","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000048/edgar.xml","form_type":"4"}},{"id":3908732,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-04T20:56:09.000Z","date":"2018-05-31","kind":"exercise","acquired":false,"shares":46651,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":100000,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":46651},"source":{"system":"sec-edgar","filing":"0001179022-18-000045","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000045/edgar.xml","form_type":"4"}},{"id":3908731,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:56:09.000Z","date":"2018-05-31","kind":"sale","acquired":false,"shares":46651,"price":5,"value":233255.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000045","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000045/edgar.xml","form_type":"4"}},{"id":3908730,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-06-04T20:56:09.000Z","date":"2018-05-31","kind":"exercise","acquired":true,"shares":46651,"price":0.87,"value":40586.37,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":47911,"source":{"system":"sec-edgar","filing":"0001179022-18-000045","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000045/edgar.xml","form_type":"4"}},{"id":3918922,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-05-24T20:51:28.000Z","date":"2018-05-22","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows: 25% on June 30, 2018, 25% on September30, 2018, and 50% on December 31, 2018."}],"balance_after":90000,"derivative":{"exercise_price":4.16,"expiration_date":"2028-05-22","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001179022-18-000041","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000041/edgar.xml","form_type":"4"}},{"id":3967788,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-04-06T20:33:06.000Z","date":"2018-04-04","kind":"exercise","acquired":false,"shares":3349,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vested as follows: 25% on December 3, 2016, the grant date; 25% on July 1, 2017; and 50% on December 31, 2017."}],"balance_after":146651,"derivative":{"exercise_price":0.87,"expiration_date":"2026-12-03","underlying":"Common Stock","underlying_shares":3349},"source":{"system":"sec-edgar","filing":"0001179022-18-000025","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000025/edgar.xml","form_type":"4"}},{"id":3967787,"issuer":{"id":5577,"kind":"organization","name":"GALECTIN THERAPEUTICS INC"},"owners":[{"id":69095,"kind":"person","name":"CALLICUTT JACK W","position":1,"cik":"0001266773","reported_name":"CALLICUTT JACK W","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-06T20:33:06.000Z","date":"2018-04-04","kind":"sale","acquired":false,"shares":3349,"price":5,"value":16745.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on February 28, 2018."}],"balance_after":1260,"source":{"system":"sec-edgar","filing":"0001179022-18-000025","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1133416/000117902218000025/edgar.xml","form_type":"4"}}],"next_cursor":"2018-04-06T20:33:06.000000Z,3967787"}